申请人:Dainippon Pharmaceutical Co., Ltd.
公开号:US04778796A1
公开(公告)日:1988-10-18
Compounds of the formula: ##STR1## wherein X is alkylene or --(CR.sub.6 .dbd.CR.sub.7).sub.r -- wherein R.sub.6 is H, alkyl or phenyl, R.sub.7 is H, alkyl, cyano or phenyl, and r is 1 or 2; A is alkylene or alkylene interrupted by at least one double bond; R.sub.1 is H, halogen, alkyl, alkoxy, alkylthio, cycloalkyloxy, cycloalkylthio, alkoxycarbonyl, carboxy, phenyl, phenoxy, phenylthio, 3-pyridyloxy or 3-pyridylthio; R.sub.2 is H, hydroxy, alkanoyloxy or alkoxycarbonyloxy, or adjacent R.sub.1 and R.sub.2 may combine to form tetramethylene or --CH.sub.2 OCR.sub.8 R.sub.9 O-- (R.sub.8 and R.sub.9 are alkyl); R.sub.3 is H, alkyl or hydroxyalkyl; R.sub.4 is H or alkyl; R.sub.5 is phenyl, heteroaryl or --(CH.sub.2).sub.m --CHR.sub.10 R.sub.11 (R.sub.10 is H or phenyl, R.sub.11 is phenyl or pyridyl and m is 0 to 2); p is 0 or 1; and q is 2 or 3; the phenyl group or moiety being optionally substituted, and a salt thereof, process for the preparation thereof, and pharmaceutical composition containing the same. Said compounds and salts thereof show excellent antiallergic activity mainly through 5-lipoxygenase inhibiting activity, antihistamine activity and/or inhibitory activity against chemical mediator release and useful for treatment of allergic diseases.
该公式化合物为:##STR1## 其中X为烷基或--(CR.sub.6.dbd.CR.sub.7).sub.r --,其中R.sub.6为H、烷基或苯基,R.sub.7为H、烷基、氰基或苯基,r为1或2;A为烷基或至少有一个双键的烷基;R.sub.1为H、卤素、烷基、烷氧基、烷硫基、环烷氧基、环烷硫基、烷氧羰基、羧基、苯基、苯氧基、苯硫基、3-吡啶氧基或3-吡啶硫基;R.sub.2为H、羟基、烷酰氧基或烷氧羰酰氧基,或相邻的R.sub.1和R.sub.2可以结合形成四亚甲基或--CH.sub.2 OCR.sub.8 R.sub.9 O--(其中R.sub.8和R.sub.9为烷基);R.sub.3为H、烷基或羟基烷基;R.sub.4为H或烷基;R.sub.5为苯基、杂环芳基或--(CH.sub.2).sub.m --CHR.sub.10 R.sub.11(其中R.sub.10为H或苯基,R.sub.11为苯基或吡啶基,m为0到2);p为0或1;q为2或3;苯基或基团可选择性地被取代;以及其盐、制备方法和含有它的药物组成物。所述化合物及其盐主要通过5-脂氧酶抑制活性、抗组胺活性和/或化学介质释放抑制活性表现出优异的抗过敏活性,并用于治疗过敏性疾病。